Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders. / Lam, J U H; Rebolj, M; Ejegod, D M; Pedersen, H; Rygaard, C; Lynge, E; Harder, E; Thomsen, L T; Kjaer, S K; Bonde, J.
In: Journal of Clinical Microbiology, Vol. 55, No. 10, 10.2017, p. 2913-2923.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders
AU - Lam, J U H
AU - Rebolj, M
AU - Ejegod, D M
AU - Pedersen, H
AU - Rygaard, C
AU - Lynge, E
AU - Harder, E
AU - Thomsen, L T
AU - Kjaer, S K
AU - Bonde, J
N1 - Copyright © 2017 Lam et al.
PY - 2017/10
Y1 - 2017/10
N2 - The Copenhagen Self-Sampling Initiative (CSi) has shown how human papillomavirus (HPV)-based self-sampling can be used to increase screening participation among 23,632 nonattenders in the Capital Region of Denmark. In this study, we describe HPV prevalence and genotype frequency in 4,824 self-samples as determined by three HPV assays (the CLART, Onclarity, and Hybrid Capture 2 [HC2] assays) and compare the results with those for physician-taken follow-up samples. The HPV self-sample findings were also compared to the findings for a reference population of 3,347 routinely screened women from the Horizon study, which had been undertaken in the same screening laboratory. Nonattenders had an HPV prevalence of 11.3% as determined by the CLART assay, which was lower than that for women from the Horizon study (18.5%). One-third of the CSi women who tested HPV positive by self-sampling tested HPV negative on the physician-taken follow-up sample. The CLART and Onclarity assays agreed on 64% (95% confidence interval [CI], 60 to 68%) of the HPV-positive self-taken samples. When the HC2 assay results were added into a three-way comparison, the level of agreement decreased to 27% (95% CI, 24 to 29%). Our findings suggest that further validation of HPV assays on self-taken samples is needed for optimal HPV detection and correct clinical management of HPV-positive women.
AB - The Copenhagen Self-Sampling Initiative (CSi) has shown how human papillomavirus (HPV)-based self-sampling can be used to increase screening participation among 23,632 nonattenders in the Capital Region of Denmark. In this study, we describe HPV prevalence and genotype frequency in 4,824 self-samples as determined by three HPV assays (the CLART, Onclarity, and Hybrid Capture 2 [HC2] assays) and compare the results with those for physician-taken follow-up samples. The HPV self-sample findings were also compared to the findings for a reference population of 3,347 routinely screened women from the Horizon study, which had been undertaken in the same screening laboratory. Nonattenders had an HPV prevalence of 11.3% as determined by the CLART assay, which was lower than that for women from the Horizon study (18.5%). One-third of the CSi women who tested HPV positive by self-sampling tested HPV negative on the physician-taken follow-up sample. The CLART and Onclarity assays agreed on 64% (95% confidence interval [CI], 60 to 68%) of the HPV-positive self-taken samples. When the HC2 assay results were added into a three-way comparison, the level of agreement decreased to 27% (95% CI, 24 to 29%). Our findings suggest that further validation of HPV assays on self-taken samples is needed for optimal HPV detection and correct clinical management of HPV-positive women.
KW - Journal Article
U2 - 10.1128/JCM.00550-17
DO - 10.1128/JCM.00550-17
M3 - Journal article
C2 - 28724554
VL - 55
SP - 2913
EP - 2923
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
SN - 0095-1137
IS - 10
ER -
ID: 184913458